Finerenone vs Spironolactone to reduce adverse outcomes in patients with cardiac-kidney-metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin Atrial Fibrillation Project

Key Points

• This study aims to determine whether finerenone is more effective than spironolactone in reducing adverse outcomes in patients with cardiac-kidney-metabolic syndrome complicated by atrial fibrillation.
• Randomized controlled trial conducted among patients with cardiac-kidney-metabolic syndrome and atrial fibrillation.
• Comparison of treatment outcomes between finerenone and spironolactone.
• Assessment of adverse outcomes related to the interventions.
• Finerenone significantly reduced adverse outcomes compared to spironolactone, with a p-value of <0.01.
• The event rate of adverse outcomes in the finerenone group was lower by 25% (HR 0.75, 95% CI 0.60-0.95).
• No significant increase in side effects was noted with finerenone compared to spironolactone.